INT103554

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2002
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 19
Total Number 19
Disease Relevance 11.23
Pain Relevance 10.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MTX1)
Anatomy Link Frequency
myometrium 1
joint 1
arm 1
MTX1 (Homo sapiens)
Pain Link Frequency Relevance Heat
methotrexate 556 100.00 Very High Very High Very High
Etanercept 71 100.00 Very High Very High Very High
rheumatoid arthritis 579 99.40 Very High Very High Very High
dexamethasone 1 98.64 Very High Very High Very High
Adalimumab 479 98.60 Very High Very High Very High
antagonist 61 97.80 Very High Very High Very High
Arthritis 367 96.16 Very High Very High Very High
cINOD 18 93.88 High High
Bioavailability 6 93.12 High High
intrathecal 8 92.72 High High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 598 99.40 Very High Very High Very High
Cancer 40 99.04 Very High Very High Very High
Necrosis 22 98.76 Very High Very High Very High
Seronegative Spondarthritis 230 98.40 Very High Very High Very High
Sprains And Strains 1 97.16 Very High Very High Very High
Toxicity 50 96.92 Very High Very High Very High
Juvenile Chronic Polyarthritis 187 96.16 Very High Very High Very High
Malaria 22 95.96 Very High Very High Very High
Disease 343 94.64 High High
INFLAMMATION 144 93.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
MTX levels in CSF 7h post-injection were 770 microM, and increased to 1250 microM 2h later.
Positive_regulation (increased) of MTX associated with methotrexate
1) Confidence 0.45 Published 2004 Journal Neurotoxicology Section Abstract Doc Link 15019303 Disease Relevance 0.73 Pain Relevance 0.62
There is evidence that anticancer compounds methotrexate (MTX) and trimetrexate (TMX) are active against both pyrimethamine (PM)-sensitive and PM-resistant laboratory strains and field isolates of Plasmodium falciparum, including those carrying the Ileu164-Leu dhfr codon (dihydrofolate reductase, DHFR), with IC50 < 85 nM (inhibitor concentration that kills 50% of parasitaemia) [11], and IC90/99 values for these folate antagonist agents fall between 150 and 350 nM; thus, if such a concentration can be achieved in vivo with an acceptable toxicity profile, these compounds could potentially be used as antimalarials.
Positive_regulation (active) of MTX associated with malaria, toxicity, antagonist, sprains and strains and methotrexate
2) Confidence 0.31 Published 2010 Journal Trends in Parasitology Section Body Doc Link PMC2927876 Disease Relevance 1.16 Pain Relevance 0.25
The differences in radiographic progression for patients treated with adalimumab versus MTX alone at Year 1 were even more marked at the end of Year 2, with an accumulated TSS change of 10.4 in the MTX monotherapy arm versus 5.5 in the adalimumab monotherapy arm and 1.9 in the combination arm.
Positive_regulation (accumulated) of MTX in arm associated with adalimumab and methotrexate
3) Confidence 0.23 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.24 Pain Relevance 1.06
Adalimumab plus MTX led to less frequent and less severe disease progression than MTX at all levels of clinical response.ACR score was a poor predictor of radiographic efficacy; therefore, radiographic monitoring may be warranted in patients regardless of their clinical response.Early TNF-antagonist therapy may be needed to prevent joint damage in patients with early RA, including some with a good clinical response to MTX monotherapy.
Positive_regulation (response) of MTX in joint associated with antagonist, rheumatoid arthritis, adalimumab, methotrexate and disease progression
4) Confidence 0.23 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 0.81 Pain Relevance 0.93
The inclusion criteria required patients to have been on MTX for at least four weeks; a high proportion of patients in the placebo group responded to MTX, demonstrating there was not an initial “incomplete response”.
Positive_regulation (responded) of MTX associated with methotrexate
5) Confidence 0.21 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2990387 Disease Relevance 0.21 Pain Relevance 0.34
Some studies of carriers of this allele suggest increased MTX efficacy [62,63], increased susceptibility to RA [65] and increased risk of toxicity [64,67,68]; however, another study did not find any effects on efficacy and toxicity [66].
Positive_regulation (increased) of MTX associated with toxicity, rheumatoid arthritis and methotrexate
6) Confidence 0.21 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691664 Disease Relevance 0.52 Pain Relevance 0.39
This deletion may be associated with decreased TYMS mRNA stability and expression [72], thereby increasing MTX efficacy [66].
Positive_regulation (increasing) of MTX associated with methotrexate
7) Confidence 0.21 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691664 Disease Relevance 0.26 Pain Relevance 0.46
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

We investigated the clinical efficacy and safety of tocilizumab (a humanized anti-IL-6 receptor antibody) monotherapy in active rheumatoid arthritis (RA) patients with an inadequate response to low dose methotrexate (MTX).

Positive_regulation (response) of MTX associated with rheumatoid arthritis, disease and methotrexate
8) Confidence 0.21 Published 2008 Journal Mod Rheumatol Section Title Doc Link PMC2638601 Disease Relevance 0.54 Pain Relevance 0.39
Therefore, tocilizumab will be useful for the patients who do not tolerate MTX.
Neg (not) Positive_regulation (tolerate) of MTX associated with methotrexate
9) Confidence 0.21 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638601 Disease Relevance 0.28 Pain Relevance 0.44
Forty-two of these 67 patients combined medication of MTX with the inhibitors of tumour necrosis factor alpha (TNF-?)
Positive_regulation (medication) of MTX associated with necrosis, cancer and methotrexate
10) Confidence 0.17 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065333 Disease Relevance 0.88 Pain Relevance 0.62
DMARDs other then MTX were used by 14 patients, six patients were treated with sulfasalazine, five patients were treated with cyklosporine A (one patient in combination with azathioprine, one patient with leflunomide, two with sulfasalazine, and the remaining patient with infliximab), four patients used parenteral or oral gold salt compounds, one patient used leflunomide, and one patient used azathioprine.
Positive_regulation (then) of MTX associated with infliximab, leflunomide and methotrexate
11) Confidence 0.17 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065333 Disease Relevance 0.74 Pain Relevance 0.66
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Positive_regulation (increased) of MTX associated with methotrexate
12) Confidence 0.17 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.38
In evaluation the efficacy of treatment in JIA groups and HLA B27 types, the data showed statisticcaly significant therapeutic effect of MTX (OR = 1.13, p < 0.03) and MTX with SS (OR = 2.02, p < 0.05) in *2705 type positive patients, but MTX with Etanercept combined therapy was necessary for *2703 type (OR = 2.94, p < 0.02) (Table 3).
Positive_regulation (necessary) of MTX associated with seronegative spondarthritis, etanercept, methotrexate and arthritis
13) Confidence 0.16 Published 2010 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2964715 Disease Relevance 1.09 Pain Relevance 0.45
Positive response to the treatment with SS was found in 32% of patients, Methotrexate (MTX) - in 43%, combined treatment - SS with MTX was effective in 12.5%. 12.5% of patients required combination MTX with Enbrel.
Positive_regulation (required) of MTX associated with methotrexate
14) Confidence 0.16 Published 2010 Journal Pediatr Rheumatol Online J Section Abstract Doc Link PMC2964715 Disease Relevance 1.58 Pain Relevance 0.75
The study was conducted at 81 centres in 18 countries in patients with active RA who had an inadequate clinical response to MTX therapy.
Positive_regulation (response) of MTX associated with rheumatoid arthritis
15) Confidence 0.16 Published 2010 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2919195 Disease Relevance 0.25 Pain Relevance 0
Nearly half of the patients in both groups were receiving MTX at baseline.
Positive_regulation (receiving) of MTX associated with methotrexate
16) Confidence 0.10 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721299 Disease Relevance 0.91 Pain Relevance 0.95
The serum adalimumab trough levels at steady state increased approximately proportionally with dose following 20, 40 and 80 mg EOW and every week s.c. dosing, and increased also with concomitant MTX.
Positive_regulation (increased) of MTX associated with adalimumab and methotrexate
17) Confidence 0.10 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721299 Disease Relevance 0.38 Pain Relevance 0.63
Increasing concentrations of GsMTx-4 (Grammostola spatulata mechanotoxin-4), a specific mechanosensitive channel blocker [35], amplified oxytocin (1 µM; OT) induced contractions in non-laboring pregnant myometrium.
Positive_regulation (Increasing) of GsMTx-4 in myometrium
18) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2928262 Disease Relevance 0.05 Pain Relevance 0
These data provide additional clinical support for elevated CSF Hcy in the induction of MTX-Ntox through activation of the NMDA-receptor.
Positive_regulation (induction) of MTX-Ntox associated with methotrexate
19) Confidence 0.01 Published 2002 Journal Pediatr Hematol Oncol Section Abstract Doc Link 12078863 Disease Relevance 0.53 Pain Relevance 0.68

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox